Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AKRO

Akero Therapeutics Inc

Dec 08 • 04:00PM ET

54.65

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Peers: MDGL ARWR HALO GNFT ALLK VKTX NBIX ENTA GALT SLDB

| Held by: VTI VXF VTWO VHT VTWG VT VTHR MSSM BTEC RESM

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.75	Insider Own	11.29%	Shs Outstand	80.15M	Perf Week	0.39%
Market Cap	4.50B	Forward P/E	-	EPS next Y	-4.00	Insider Trans	-2.65%	Shs Float	73.02M	Perf Month	1.37%
Enterprise Value	3.76B	PEG	-	EPS next Q	-0.92	Inst Own	103.53%	Short Float	5.75%	Perf Quarter	22.48%
Income	-292.82M	P/S	-	EPS this Y	3.20%	Inst Trans	-	Short Ratio	1.65	Perf Half Y	-0.11%
Sales	0.00M	P/B	4.57	EPS next Y	-10.06%	ROA	-32.12%	Short Interest	4.20M	Perf YTD	96.44%
Book/sh	11.95	P/C	6.10	EPS next 5Y	-6.97%	ROE	-34.53%	52W High	58.40 -6.42%	Perf Year	76.75%
Cash/sh	8.96	P/FCF	-	EPS past 3/5Y	-9.07% -5.28%	ROIC	-30.57%	52W Low	21.34 156.09%	Perf 3Y	19.61%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	0.49% 0.31%	Perf 5Y	89.43%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-0.06%	Oper. Margin	-	ATR (14)	0.29	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	15.83	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	69.17	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	15.83	EPS Q/Q	5.00%	SMA20	0.50%	Beta	-0.36	Target Price	55.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	3.27%	Rel Volume	0.00	Prev Close	54.65
Employees	63	LT Debt/Eq	0.00	Earnings	Nov 12	SMA200	13.46%	Avg Volume	2.55M	Price	54.65
IPO	Jun 20, 2019	Option/Short	Yes / No	EPS/Sales Surpr.	0.94% -	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-04-25	Resumed	H.C. Wainwright	Buy	$72
Aug-04-25	Initiated	TD Cowen	Buy	$76
Jan-30-25	Upgrade	BofA Securities	Neutral → Buy	$35 → $63
Jan-27-25	Reiterated	H.C. Wainwright	Buy	$50 → $72
Nov-18-24	Initiated	Citigroup	Buy	$65
Apr-22-24	Resumed	BofA Securities	Neutral	$30
Sep-19-23	Initiated	Cantor Fitzgerald	Overweight	$69
Aug-28-23	Initiated	UBS	Buy	$83
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$40 → $65
Sep-14-22	Upgrade	Evercore ISI	In-line → Outperform	$10 → $50
Oct-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$27
Sep-10-21	Initiated	BofA Securities	Buy	$40
Feb-26-21	Initiated	Guggenheim	Buy	$54
Sep-10-20	Initiated	Morgan Stanley	Overweight	$70
Jul-20-20	Reiterated	H.C. Wainwright	Buy	$45 → $62
Jul-07-20	Initiated	Chardan Capital Markets	Buy	$79
Jul-01-20	Reiterated	H.C. Wainwright	Buy	$33 → $45
Mar-02-20	Initiated	H.C. Wainwright	Buy	$33
Feb-10-20	Initiated	Canaccord Genuity	Buy	$36
Jul-15-19	Initiated	ROTH Capital	Buy	$34

Show Previous Ratings

Nov-18-25 12:20PM	Halper Sadeh LLC Encourages WOW, AKRO, HFWA, BRY Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Nov-12-25 01:55PM	Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Nov-07-25 07:00AM	Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting 2025 (GlobeNewswire)
Nov-06-25 03:02PM	Biotech M&A Deals Are Trickier Than They Look. Watch the Milestone Payments. (Barrons.com)
Nov-05-25 11:45AM	Halper Sadeh LLC Encourages AKRO, CADE, FSUN Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
04:30PM	Loading…
Nov-04-25 04:30PM	Novo Nordisk Reports Earnings on Wednesday. What to Expect. (Barrons.com)
Nov-02-25 05:30AM	Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk (The Wall Street Journal)
Oct-30-25 06:31AM	Novo Nordisk Offers $6.5 Billion for Metsera to Challenge Pfizer (Bloomberg)
Oct-29-25 09:06AM	Halper Sadeh LLC Encourages FFWM, AKRO, CCRD Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Oct-13-25 05:30AM	Why Biotech's Rally Can Last This Time (The Wall Street Journal)
Oct-10-25 12:21PM	CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza (Zacks)
12:19PM	Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. (Barrons.com)
10:27AM	OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data (Zacks)
09:54AM	Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance? (Zacks)
06:35AM	Earnings, Fed Rates Mean Stocks Can Ignore the Shutdown. This Could Change That. (Barrons.com)
06:30AM	Loading…
06:30AM	Novo Nordisk Seeks to Expand Liver Disease Treatments in $5.2B Deal for Bay Area Biotech (The Daily Upside)
Oct-09-25 10:32PM	Akero Therapeutics (AKRO) Jumps 16% on $5.2-Billion Novo Nordisk Merger (Insider Monkey) +16.33%
04:48PM	Why Akero Therapeutics Stock Trounced the Market on Thursday (Motley Fool)
12:19PM	Top Stock Movers Now: Delta Air Lines, PepsiCo, Akero Therapeutics, and More (Investopedia)
11:17AM	Novo Nordisk Is Buying Akero Therapeutics. Its More Good News for Biotech Stocks. (Barrons.com)
10:11AM	Akero Therapeutics Stock Surges on Novo Nordisk Buyout (Schaeffer's Research)
10:08AM	Novo Nordisk buys MASH specialist Akero for up to $5.2bn (Pharmaceutical Technology)
09:41AM	Stocks to Watch Thursday: PepsiCo, Delta, MP Materials, Nvidia (The Wall Street Journal)
08:58AM	Stock Market Today: Dow Wavers Amid Results For Nvidia Chipmaker, Delta. Tesla Faces Probe (Live Coverage) (Investor's Business Daily)
08:56AM	Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $4.7 Billion Buyout (Investor's Business Daily)
07:31AM	Akero Therapeutics Stock Soars. Novo Nordisk Is Buying the Biotech for up to $5.2 Billion. (Barrons.com)
06:59AM	Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease (MarketWatch)
06:39AM	Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion (The Wall Street Journal)
06:39AM	Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion (The Wall Street Journal)
06:01AM	Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion (GlobeNewswire)
11:18AM	Loading…
Oct-08-25 11:18AM	KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure (Zacks)
11:15AM	AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study (Zacks)
Oct-07-25 11:56AM	MRK Expands Tulisokibart Program in Three New Inflammatory Diseases (Zacks)
07:00AM	Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting 2025 (GlobeNewswire)
Oct-01-25 09:40AM	Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-26-25 10:32AM	LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy (Zacks)
Sep-24-25 04:47AM	Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience (Zacks)
Sep-23-25 12:08PM	CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU (Zacks)
09:23AM	5 Biotech Stocks Worth Adding to Your Portfolio Now (Zacks)
Sep-19-25 12:24PM	NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up (Zacks)
Sep-16-25 12:54PM	Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update (Zacks)
Sep-15-25 09:40AM	Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year? (Zacks)
Sep-11-25 11:57AM	FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer (Zacks)
Sep-10-25 11:11AM	IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome (Zacks)
Sep-05-25 11:00AM	AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA (Zacks)
10:04AM	AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia (Zacks)
Sep-04-25 10:48AM	SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study (Zacks)
Sep-01-25 12:30PM	Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia (Zacks)
Aug-28-25 09:40AM	Has Akero Therapeutics (AKRO) Outpaced Other Medical Stocks This Year? (Zacks)
07:00AM	Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire)
Aug-27-25 09:55AM	Does Akero Therapeutics (AKRO) Have the Potential to Rally 59.14% as Wall Street Analysts Expect? (Zacks)
Aug-21-25 11:13AM	RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study (Zacks)
Aug-14-25 06:30PM	Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH (GlobeNewswire)
11:11AM	Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
Aug-12-25 09:40AM	Are Medical Stocks Lagging Akero Therapeutics (AKRO) This Year? (Zacks)
Aug-08-25 07:15AM	Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-04-25 09:35AM	Coinbase downgraded, Spotify upgraded: Wall Street's top analyst calls (The Fly)
Jul-25-25 08:46AM	Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
Jul-24-25 12:10PM	Amarin Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
11:42AM	Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards? (Zacks)
10:45AM	VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales (Zacks)
Jul-23-25 10:53AM	Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth? (Zacks)
Jul-21-25 09:38AM	Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect (Zacks)
Jul-18-25 11:28AM	RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure (Zacks)
10:39AM	FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo (Zacks)
Jul-17-25 01:07PM	AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies (Zacks)
10:02AM	Mirum Gains 35% in 3 Months: How Should You Play the Stock? (Zacks)
Jul-16-25 11:54AM	Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag (Zacks)
Jul-15-25 10:17AM	Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer (Zacks)
Jun-03-25 07:00AM	Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-28-25 07:00AM	Akero Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 11:51PM	Why Akero Therapeutics, Inc. (AKRO) Skyrocketed Today (Insider Monkey) +24.72%
May-13-25 08:10AM	Best Biotech Stocks to Buy in 2025 (MarketBeat)
May-12-25 07:00AM	Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-11-25 05:21PM	Why Akero Therapeutics (AKRO) Is Among the Best Performing Healthcare Stocks to Buy Now (Insider Monkey)
May-10-25 10:00AM	Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025 (GlobeNewswire)
May-09-25 07:41AM	Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025 (GlobeNewswire) -5.99%
07:11AM	Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine (GlobeNewswire)
May-07-25 04:05PM	Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference (GlobeNewswire)
Apr-30-25 07:00AM	Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025 (GlobeNewswire) +5.97%
Apr-18-25 04:46AM	89bio: A Buy With Strong Market Opportunity In MASH And SHTG (Seeking Alpha)
Apr-17-25 10:28AM	89bio: Primary Asset Targeting 2 Potential Indications And Is In Late-Stage Development (Seeking Alpha)
Apr-06-25 01:47PM	Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock (Seeking Alpha)
Mar-24-25 09:13AM	Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-02-25 09:34AM	Why Akero Therapeutics, Inc. (AKRO) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-28-25 07:00AM	Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-25 01:23PM	Is Akero Therapeutics Inc. (AKRO) the Best Performing Mid Cap Stock to Buy According to Analysts? (Insider Monkey)
Feb-23-25 03:18PM	Akero Therapeutics, Inc. (AKRO): the Best Performing Pharma Stock So Far in 2025 (Insider Monkey)
Feb-20-25 08:42AM	Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino's Pizza Corp. (NASDAQ: DPZ) (GlobeNewswire)
Feb-19-25 02:45PM	Akero Therapeutics, Inc. (AKRO): the Best Performing Healthcare Stock So Far in 2025 (Insider Monkey)
Feb-03-25 07:25PM	Why Akero Therapeutics Inc (AKRO) Is Skyrocketing So Far In 2025 (Insider Monkey)
12:28PM	Akero Therapeutics Inc. (AKRO): Among The Stocks That Started The Year On A High (Insider Monkey)
Feb-02-25 06:21PM	This Stock Just Doubled in 1 Day -- Is It Still a Buy? (Motley Fool)
04:35PM	Why Akero Therapeutics (AKRO) Is Among the Best Booming Stocks to Invest in Now? (Insider Monkey)
Jan-30-25 04:05PM	Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-29-25 05:39AM	BioAge drops obesity drug; Akero, 89bio cash in on MASH data (BioPharma Dive)
Jan-28-25 09:30PM	Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
11:14AM	Akeros cirrhosis treatment shows promise in Phase IIb study (Clinical Trials Arena)
08:40AM	Why Akero Therapeutics Inc. (AKRO) Surged on Monday (Insider Monkey)
Jan-27-25 04:24PM	Akero Therapeutics Stock Nearly Doubles Pulling 89bio Higher On Positive MASH Study (Investor's Business Daily) +97.52%

Akero Therapeutics is a biopharmaceutical company focused on developing therapies for patients with serious metabolic diseases. The company's pipeline centers on the development of Efruxifermin (EFX) for the treatment of pre-cirrhotic MASH, formerly known as NASH. Akero Therapeutics conducts clinical trials and research programs related to its therapeutic focus.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rolph Timothy	Chief Scientific Officer	Nov 25 '25	Option Exercise	4.09	152,678	624,087	282,149	Nov 28 06:03 AM
Young Jonathan	Chief Operating Officer	Nov 24 '25	Option Exercise	23.13	12,550	290,333	209,448	Nov 26 04:03 PM
Yale Catriona	Chief Development Officer	Nov 04 '25	Option Exercise	24.19	8,266	199,983	74,800	Nov 06 07:00 AM
Cheng Andrew	President and CEO	Oct 10 '25	Option Exercise	19.87	30,000	596,100	556,114	Oct 14 08:11 PM
Cheng Andrew	President and CEO	Oct 10 '25	Sale	53.98	30,000	1,619,340	526,114	Oct 14 08:11 PM
Graham G. Walmsley	Director	Oct 08 '25	Option Exercise	20.55	90,832	1,866,155	93,000	Oct 10 07:48 PM
Rolph Timothy	Chief Scientific Officer	Oct 07 '25	Option Exercise	28.35	12,500	354,375	179,071	Oct 09 06:58 PM
Rolph Timothy	Chief Scientific Officer	Oct 07 '25	Sale	46.08	12,500	576,001	166,571	Oct 09 06:58 PM
Cheng Andrew	President and CEO	Oct 08 '25	Option Exercise	0.61	52,212	32,110	526,114	Oct 09 06:58 PM
Timothy Rolph	Officer	Oct 07 '25	Proposed Sale	46.04	56,369	2,595,229		Oct 07 04:11 PM
Young Jonathan	Chief Operating Officer	Oct 01 '25	Option Exercise	21.10	12,500	263,750	209,398	Oct 03 04:30 PM
Young Jonathan	Chief Operating Officer	Oct 01 '25	Sale	47.76	12,500	596,978	196,898	Oct 03 04:30 PM
Young Jonathan	Chief Operating Officer	Sep 11 '25	Sale	43.02	586	25,210	196,898	Sep 12 08:39 PM
Yale Catriona	Chief Development Officer	Sep 11 '25	Sale	43.02	659	28,350	90,829	Sep 12 08:39 PM
White William Richard	Chief Financial Officer	Sep 11 '25	Sale	43.02	659	28,350	57,752	Sep 12 08:38 PM
Rolph Timothy	Chief Scientific Officer	Sep 11 '25	Sale	43.02	553	23,790	166,571	Sep 12 08:36 PM
Cheng Andrew	President and CEO	Sep 10 '25	Option Exercise	8.10	14,941	121,003	505,698	Sep 12 08:36 PM
Cheng Andrew	President and CEO	Sep 10 '25	Sale	43.25	30,000	1,297,401	475,698	Sep 12 08:36 PM
Cheng Andrew	President and CEO	Sep 11 '25	Sale	43.02	1,796	77,264	473,902	Sep 12 08:36 PM
Rolph Timothy	Chief Scientific Officer	Sep 08 '25	Option Exercise	15.18	12,500	189,766	179,624	Sep 10 07:48 PM
Rolph Timothy	Chief Scientific Officer	Sep 08 '25	Sale	44.17	12,500	552,137	167,124	Sep 10 07:48 PM
Andrew Cheng	President, CEO and Director	Sep 10 '25	Proposed Sale	44.62	90,000	4,015,800		Sep 10 05:46 PM
Young Jonathan	Chief Operating Officer	Sep 02 '25	Option Exercise	21.10	12,500	263,750	209,984	Sep 04 07:47 PM
Young Jonathan	Chief Operating Officer	Sep 02 '25	Sale	46.08	12,500	576,035	197,484	Sep 04 07:47 PM
Gangloff Scott A.	Chief Technology Officer	Aug 15 '25	Option Exercise	19.62	2,600	51,012	26,351	Aug 19 09:32 PM
Young Jonathan	Chief Operating Officer	Aug 12 '25	Option Exercise	21.10	12,500	263,750	209,984	Aug 13 06:37 PM
Young Jonathan	Chief Operating Officer	Aug 12 '25	Sale	47.79	12,500	597,326	197,484	Aug 13 06:37 PM
Cheng Andrew	President and CEO	Aug 11 '25	Sale	48.59	30,000	1,457,596	490,757	Aug 13 06:37 PM
Henderson Jane	Director	Aug 12 '25	Option Exercise	7.01	3,000	21,027	12,398	Aug 12 08:32 PM
Henderson Jane	Director	Aug 12 '25	Sale	47.46	3,000	142,371	9,398	Aug 12 08:32 PM
Jonathan Young	Officer	Aug 12 '25	Proposed Sale	48.28	50,000	2,414,000		Aug 12 04:59 PM
JANE HENDERSON	Director	Aug 12 '25	Proposed Sale	47.46	3,000	142,372		Aug 12 04:07 PM
Rolph Timothy	Chief Scientific Officer	Aug 05 '25	Option Exercise	21.09	12,500	263,625	179,624	Aug 07 09:00 AM
Rolph Timothy	Chief Scientific Officer	Aug 05 '25	Sale	49.30	12,500	616,299	167,124	Aug 07 09:00 AM
Yale Catriona	Chief Development Officer	Jul 16 '25	Option Exercise	19.87	10,000	198,700	101,488	Jul 18 06:00 PM
Yale Catriona	Chief Development Officer	Jul 16 '25	Sale	52.95	10,000	529,467	91,488	Jul 18 06:00 PM
Cheng Andrew	President and CEO	Jul 10 '25	Sale	51.16	30,000	1,534,895	520,757	Jul 11 06:30 PM
Rolph Timothy	Chief Scientific Officer	Jul 07 '25	Option Exercise	21.09	12,500	263,625	179,624	Jul 09 07:00 PM
Rolph Timothy	Chief Scientific Officer	Jul 07 '25	Sale	51.09	12,500	638,661	167,124	Jul 09 07:00 PM
Timothy Rolph	Officer	Jul 07 '25	Proposed Sale	51.85	56,250	2,916,563		Jul 07 04:27 PM
Lamy Patrick	Senior VP, Commercial Strategy	Jul 01 '25	Sale	52.88	2,000	105,760	29,891	Jul 03 06:00 PM
PATRICK D LAMY	Officer	Jul 01 '25	Proposed Sale	53.36	2,000	106,720		Jul 01 04:26 PM
Cheng Andrew	President and CEO	Jun 18 '25	Sale	54.84	6,620	363,041	549,867	Jun 20 09:09 PM
Gangloff Scott A.	Chief Technology Officer	Jun 18 '25	Sale	54.84	848	46,504	23,452	Jun 20 09:08 PM
Lamy Patrick	Senior VP, Commercial Strategy	Jun 20 '25	Sale	54.59	875	47,766	31,698	Jun 20 09:08 PM
Rolph Timothy	Chief Scientific Officer	Jun 18 '25	Sale	54.84	1,129	61,914	166,234	Jun 20 09:07 PM
White William Richard	Chief Financial Officer	Jun 18 '25	Sale	54.84	1,634	89,609	57,521	Jun 20 09:07 PM
Yale Catriona	Chief Development Officer	Jun 18 '25	Sale	54.84	1,633	89,554	90,598	Jun 20 09:07 PM
Young Jonathan	Chief Operating Officer	Jun 18 '25	Sale	54.84	1,453	79,683	196,594	Jun 20 09:06 PM
Yale Catriona	Chief Development Officer	Jun 16 '25	Option Exercise	21.10	10,000	211,000	102,231	Jun 20 09:22 AM
Yale Catriona	Chief Development Officer	Jun 16 '25	Sale	54.23	10,000	542,306	92,231	Jun 20 09:22 AM
Lamy Patrick	Senior VP, Commercial Strategy	Jun 16 '25	Option Exercise	19.87	2,000	39,740	34,573	Jun 20 09:22 AM
Lamy Patrick	Senior VP, Commercial Strategy	Jun 16 '25	Sale	54.14	2,000	108,272	32,573	Jun 20 09:22 AM
Cheng Andrew	President and CEO	Jun 10 '25	Sale	54.05	37,837	2,044,940	556,487	Jun 12 06:34 PM
Rolph Timothy	Chief Scientific Officer	Jun 10 '25	Sale	54.00	2,358	127,323	167,363	Jun 12 06:33 PM
White William Richard	Chief Financial Officer	Jun 10 '25	Sale	53.99	2,804	151,402	59,155	Jun 12 06:33 PM
Yale Catriona	Chief Development Officer	Jun 10 '25	Sale	54.00	2,803	151,351	92,231	Jun 12 06:33 PM
Lamy Patrick	Senior VP, Commercial Strategy	Jun 10 '25	Sale	54.00	919	49,625	32,573	Jun 12 06:32 PM
Young Jonathan	Chief Operating Officer	Jun 10 '25	Sale	53.99	2,493	134,605	198,047	Jun 12 06:32 PM
Rolph Timothy	Chief Scientific Officer	Jun 06 '25	Option Exercise	21.09	25,000	527,254	194,721	Jun 09 05:30 PM
Rolph Timothy	Chief Scientific Officer	Jun 05 '25	Option Exercise	21.10	12,500	263,750	182,221	Jun 09 05:30 PM
Rolph Timothy	Chief Scientific Officer	Jun 06 '25	Sale	55.04	25,000	1,376,000	169,721	Jun 09 05:30 PM
Rolph Timothy	Chief Scientific Officer	Jun 05 '25	Sale	53.49	12,500	668,634	169,721	Jun 09 05:30 PM
Lamy Patrick	Senior VP, Commercial Strategy	Jun 02 '25	Option Exercise	19.87	4,000	79,480	37,492	Jun 04 05:36 PM
Lamy Patrick	Senior VP, Commercial Strategy	Jun 02 '25	Sale	50.31	4,000	201,258	33,492	Jun 04 05:36 PM
Lamy Patrick	Senior VP, Commercial Strategy	May 22 '25	Option Exercise	44.37	4,000	177,480	37,492	May 23 05:30 PM
Lamy Patrick	Senior VP, Commercial Strategy	May 22 '25	Sale	50.00	4,000	200,000	33,492	May 23 05:30 PM
PATRICK D LAMY	Officer	May 22 '25	Proposed Sale	48.35	10,000	483,500		May 22 04:20 PM
Yale Catriona	Chief Development Officer	May 15 '25	Option Exercise	21.10	10,000	211,000	105,034	May 19 07:06 PM
Yale Catriona	Chief Development Officer	May 15 '25	Sale	39.30	10,000	392,978	95,034	May 19 07:06 PM
CATRIONA YALE	Officer	May 15 '25	Proposed Sale	37.88	30,000	1,136,400		May 15 04:27 PM
Cheng Andrew	President and CEO	May 12 '25	Sale	41.48	30,000	1,244,455	594,324	May 13 09:11 PM
Andrew Cheng	Officer	May 12 '25	Proposed Sale	39.85	120,000	4,782,000		May 12 06:47 PM
Lamy Patrick	Senior VP, Commercial Strategy	May 07 '25	Option Exercise	19.87	8,000	158,960	41,492	May 09 07:18 PM
Lamy Patrick	Senior VP, Commercial Strategy	May 07 '25	Sale	42.49	8,000	339,950	33,492	May 09 07:18 PM
Rolph Timothy	Chief Scientific Officer	May 06 '25	Option Exercise	21.10	12,500	263,750	182,221	May 08 07:34 PM
Rolph Timothy	Chief Scientific Officer	May 06 '25	Sale	43.43	12,500	542,864	169,721	May 08 07:34 PM
Timothy Rolph	Officer	May 06 '25	Proposed Sale	40.00	50,000	2,000,000		May 06 04:41 PM
Rolph Timothy	Chief Scientific Officer	Apr 24 '25	Option Exercise	21.10	6,250	131,875	175,971	Apr 28 06:22 PM
Rolph Timothy	Chief Scientific Officer	Apr 24 '25	Sale	41.03	6,250	256,438	169,721	Apr 28 06:22 PM
Yale Catriona	Chief Development Officer	Apr 15 '25	Option Exercise	21.10	9,073	191,440	104,107	Apr 16 06:00 PM
Yale Catriona	Chief Development Officer	Apr 15 '25	Sale	37.91	9,073	343,962	95,034	Apr 16 06:00 PM
Cheng Andrew	President and CEO	Apr 10 '25	Sale	35.23	30,000	1,056,780	624,324	Apr 11 06:00 PM
Rolph Timothy	Chief Scientific Officer	Apr 07 '25	Option Exercise	21.10	6,250	131,875	175,971	Apr 10 06:00 PM
Rolph Timothy	Chief Scientific Officer	Apr 07 '25	Sale	35.88	6,250	224,262	169,721	Apr 10 06:00 PM
PATRICK D LAMY	Officer	Apr 07 '25	Proposed Sale	36.73	8,000	293,840		Apr 07 04:24 PM
Graham G. Walmsley	Director	Mar 25 '25	Buy	44.75	91,309	4,085,804	1,091,309	Mar 27 07:42 PM
Graham G. Walmsley	Director	Mar 26 '25	Buy	43.01	58,691	2,524,417	1,150,000	Mar 27 07:42 PM
Graham G. Walmsley	Director	Mar 27 '25	Buy	43.55	50,000	2,177,700	1,200,000	Mar 27 07:42 PM
Yale Catriona	Chief Development Officer	Mar 17 '25	Option Exercise	21.10	10,000	211,000	105,034	Mar 18 05:30 PM
Yale Catriona	Chief Development Officer	Mar 17 '25	Sale	44.76	10,000	447,605	95,034	Mar 18 05:30 PM
Cheng Andrew	President and CEO	Mar 12 '25	Sale	44.88	1,738	78,001	654,324	Mar 14 09:18 PM
Young Jonathan	Chief Operating Officer	Mar 12 '25	Sale	44.88	607	27,242	200,540	Mar 14 08:33 PM
Yale Catriona	Chief Development Officer	Mar 12 '25	Sale	44.88	614	27,556	95,034	Mar 14 08:30 PM
White William Richard	Chief Financial Officer	Mar 12 '25	Sale	44.88	676	30,339	61,959	Mar 14 08:24 PM
Rolph Timothy	Chief Scientific Officer	Mar 12 '25	Sale	44.88	516	23,158	169,721	Mar 14 08:18 PM
Cheng Andrew	President and CEO	Mar 10 '25	Sale	41.77	30,000	1,253,069	656,062	Mar 12 06:00 PM
Rolph Timothy	Chief Scientific Officer	Mar 05 '25	Option Exercise	21.10	12,500	263,750	182,737	Mar 07 05:30 PM
Rolph Timothy	Chief Scientific Officer	Mar 05 '25	Sale	44.53	12,500	556,590	170,237	Mar 07 05:30 PM
Young Jonathan	Chief Operating Officer	Mar 04 '25	Sale	44.86	50,000	2,243,213	201,147	Mar 05 06:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AKRO

Akero Therapeutics Inc

Upgrade your FINVIZ experience